1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Shenzhen Weiguang Biological Products Co., Ltd. Class A

Shenzhen Weiguang Biological Products Co., Ltd. Class A

SSZSE:002880
19.70
CNY
+0.09
(+0.46%)
0.87EPS
22.46P/E
4.42BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.09
2.66
2.94
3.33
3.15
3.03
5.43
5.58
4
2.95
4.62
5.31
5.59
5.37
Basic EPS, GAAP
0.52
0.59
0.73
0.9
0.78
0.69
1.13
1.18
0.91
0.52
0.96
1.12
1.09
0.87
Free Cash Flow per Basic Share
-0.21
0.56
0.38
0.39
-0.17
0.07
0.71
0.71
0.03
-1.44
0.3
-0.34
0.41
- -
Dividend per Share
0.74
0.22
0.41
0.35
0.47
0.25
0.22
0.22
0.18
0.25
0.29
0.29
0.29
0.27
Book Value per Share
1.32
1.82
2.31
2.98
5.3
5.77
6.38
7.07
7.8
8.12
8.88
9.75
10.64
10.63
Tangible Book Value per Share
0.84
1.25
1.75
2.42
4.89
5.31
5.89
6.58
7.31
7.61
8.1
8.95
9.71
9.7
Basic Weighted Avg Shares
170
170
170
170
198
227
151
162
227
227
227
227
227
227
Sales/Revenue/Turnover
355
453
501
566
623
688
821
905
907
668
1,049
1,203
1,267
1,218
Operating Margin (%)
31.76
31.29
32.6
32.85
30.88
26.98
24.59
23.44
26.12
17.54
23.76
27.5
25.58
22.25
Depreciation Expense
30
39
40
40
42
42
40
46
55
65
87
118
155
- -
Net Income, GAAP
89
101
125
153
155
157
171
190
205
118
219
254
246
197
Effective Tax Rate (%)
14.68
14.68
14.27
14.63
14.4
13.85
13.69
13.45
15
11.73
11.37
14.42
13.16
15.81
Profit Margin (%)
25.02
22.21
24.92
27.07
24.82
22.77
20.86
21.05
22.64
17.59
20.85
21.07
19.45
16.15
Working Capital
-9
4
94
166
778
813
905
936
832
903
838
1,105
974
930
LT Debt
112
39
97
76
24
- -
- -
- -
17
446
500
569
508
484
Total Equity
224
309
394
506
1,203
1,309
1,449
1,624
1,788
1,868
2,046
2,244
2,445
2,444
Return on Invested Capital (%)
15.25
14.84
16.68
18.35
14.68
11.96
12.29
12.06
11.54
5.71
8.75
9.19
7.92
6.34
Return on Capital (%)
20.43
19.21
20.56
21.64
15.98
12.25
12.34
12.18
11.77
5.45
9.33
9.88
8.53
6.86
Return on Common Equity (%)
49.53
37.74
35.54
34.04
18.1
12.47
12.43
12.48
12.18
6.51
11.34
12
10.65
8.43

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
331
317
338
LT Borrowings
493
481
469
LT Finance Leases
15
15
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
227
227
227
Market Capitalization
5,783
6,108
4,418

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,686
1,468
1,529
Cash, Cash Equivalents & STI
370
77
83
Accounts Receivable, Net
303
390
343
Inventories
883
951
1,010
Total Current Liabilities
712
621
599
Payables & Accruals
- -
- -
- -
ST Debt
331
317
338
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.05%
8.55%
8.95%
Free Cash Flow
-579.86%
-1,226.26%
-220.27%
Net Income, GAAP
10.97%
12.85%
-2.84%
Sales/Revenue/Turnover
11.39%
10.19%
5.28%
Total Cash Common Dividend
4.1%
13.81%
-0.23%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
226
297
331
349
1,203
2025
225
293
- -
476
1,267
2026
222
227
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.28
0.32
0.31
1.12
2025
0.19
0.28
- -
0.39
1.09
2026
0.14
0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.22
0.02
0.29
2025
0.02
0.02
- -
0.02
0.29
2026
0.02
0.22
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Cai Ping Guo
Full Time Employees
901
Sector
Health technology
Industry
Biotechnology
Address
No. 3402, Guangqiao Avenue Shenzhen GD China 518107
IPO Date
Jun 16, 2017
Website
szwg.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Shenzhen Weiguang Biological Products Co., Ltd. specializes in the research, development, production, and sale of biological and blood products. The company's core product portfolio includes human serum albumin; intravenous human immunoglobulin (pH4); freeze-dried intravenous human immunoglobulin; hepatitis B human immunoglobulin; rabies human immunoglobulin; tetanus human immunoglobulin; histamine human immunoglobulin; human fibrinogen; and coagulation factors, with a total of 9 varieties and 21 specifications. It operates a state-of-the-art manufacturing facility in Shenzhen, China, where it is headquartered. Founded in 1985, the company primarily serves the Chinese domestic market while also exporting to over 25 countries across Asia, Europe, and North America. In recent developments, Shenzhen Weiguang has enhanced its product portfolio with investments focusing on innovative biologics, including plans for a novel mRNA vaccine project projected to enter clinical trials. The company received China FDA approval for clinical trials related to human coagulation factor VIII, marking a significant step in its biopharmaceutical pipeline. It continues to allocate substantial funding to research and development, with an emphasis on vaccines, diagnostic reagents, and advanced drug delivery systems, targeting at least three new product launches within the next two years. Shenzhen Weiguang is recognized as a national high-tech enterprise and the sole blood product enterprise listed in Shenzhen. It holds a notable position in China's biopharmaceutical sector with around a 12% domestic market share as of 2023. Its strategic focus combines innovation with quality control and operational efficiency, supported by approximately 1,200 employees, including a substantial R&D workforce. The company’s revenue streams are diversified across vaccines (human and animal), diagnostic reagents, and health products, with vaccines constituting the majority of sales. Its growing export footprint and strategic partnerships position it for continued expansion in global markets.